Scalp Psoriasis Clinical Trial

STUDY BASICS

Are you 18 or over with moderate to severe scalp psoriasis? You may be eligible to participate in a research study to measure how safe and effective the investigational drug BMS-986165 (also known as deucravacitinib) is in treating participants with scalp psoriasis. Reimbursement available.

STUDY PURPOSE

The purpose of this study is to measure how safe and effective the investigational drug BMS-986165 (also known as deucravacitinib) is in treating participants with scalp psoriasis.Psoriasis is a chronic inflammatory skin disorder, characterized primarily by scaly plaques, that affects up to 3% of the general population. Up to eighty percent (80%) of people living with psoriasis may have scalp psoriasis. It can affect the scalp, hairline, forehead, back of the neck and skin around the ears.

COULD THIS STUDY BE RIGHT FOR YOU?

• Age 18 or older
• Have moderate to severe scalp psoriasis

WHAT PARTICIPANTS CAN EXPECT

If you are enrolled, the duration of your participation is 60 weeks as follows:
• Screening (up to 4 weeks)
• Study treatment (52 weeks)
• Follow-up (4 weeks)

This will involve approximately 15 visits to your study doctor.